Bayer sees strong pharma growth despite Xarelto decline

5 March 2025

German life science giant Bayer (BAYN: DE) has reported 2024 group revenue of 47.6 billion euros ($51.5 billion), down 2.2% from the previous year. Core earnings per share fell 21% to 5.05 euros, while earnings before interest, tax, depreciation and amortization (EBITDA) before special items declined 13.5% to 10.1 billion euros.

The pharmaceutical division generated 18.1 billion euros in revenue, a 3.3% increase on a currency- and portfolio-adjusted basis. However, EBIT for the unit fell 29.7% to 2.79 billion euros, impacted by unfavorable product mix shifts and higher licensing costs.

In the fourth quarter, pharma revenue rose 2.4% to 4.66 billion euros, while earning per share (EPS) dropped 43% to 1.05 euros. Overall, investors reacted positively to the results, sending shares in the company up over 6%.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK